NRG1 and neoplasm: However, we decided to use a larger panel of 50 genes at tumor diagnosis in order to have a larger molecular portrait of the tumor, including information on the main exons of TP53 (since TP53 mutations may have an impact soon on treatment decision-making), but also on other potential therapeutic targets associated with genomic alteration on different genes such as NRG1, PI3KA, and other genes.